GENE ONLINE|News &
Opinion
Blog

2019-nCoV
COVID-19
Weekly Cover : Fosun and BioNTech Invest USD 135m for Covid-19 Vaccine
2020-03-19
COVID-19 Virus Suppressing Factor
Weekly Cover: Takeda Initiates Development of Potential COVID-19 Therapy TAK-888
2020-03-13
In-Depth COVID-19
Understanding the Scientific Challenges in Combating the New Coronavirus
2020-02-11
COVID-19
Weekly Cover: Expansion of Samsung Biologics Projects into U.S. and Europe
2020-02-11
COVID-19 Vaccine
Weekly cover : Companies Developing 2019-nCoV Vaccine
2020-02-04
COVID-19 WHO
WHO Declares 2019-nCoV Outbreak, a Global Health Emergency
2020-01-31
COVID-19
Update On 2019 Novel Coronavirus (2019-nCov): The Latest Progress In Vaccine Development And Treatment
2020-01-30
Taiwan
Weekly Cover: LATEST Cell Therapy Trend in Taiwan& 2019-nCoV Outbreak
2020-01-23
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
READ MORE
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top